MCM
ELVN icon

MAI Capital Management’s Enliven Therapeutics ELVN Stock Holding History

MAI Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7
Closed -$275 – 2831
2026
Q1 		$275 Buy
+7
New +$194 ﹤0.01% 4549

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

MAI Capital Management's ELVN Position: Q2 2026 in Review

MAI Capital Management sold out of Enliven Therapeutics (ELVN) in Q2 2026, closing a stake of 7 shares — an estimated $275 sold.

MAI Capital Management first reported a position in ELVN in Q1 2026 and held it in 1 quarter. The position peaked at $275 in Q1 2026. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • MAI Capital Management reported no remaining Enliven Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 7 Enliven Therapeutics shares in Q2 2026, an estimated $275.
  • MAI Capital Management first reported a position in Enliven Therapeutics in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's Enliven Therapeutics position peaked at $275 in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.